At the beginning of Haisco, R&D Center exclusively developed Carbohydrate and Electrolyte Injection and Acetaminophen methionine capsule, first developed fructose and its injection, Fructose and Sodium Chloride Injection. Furthermore, those products has transferred to some famo
us pharmaceuticals in China, which gained great social benefit and economic benefit, some of them became the most profitable products. R&D Center is on the top of China in high-end sugar infusion novel drug development.
After years a torrent of aboundant investment and accumulation, R&D Center has successfully developed 24 novel products and 15 of them are on the market through contract manufacture, which covers anti-infection, digestive system, hematological system, nervous system, parenteral nutrition and so on therapy areas. The new core products include: Invert Sugar Injection, Invert Sugar and Electrolytes Injection, Sodium Fusidate for Injection, Polyene Phosphatidylcholine Injection (Essentiale), Fat-soluble Vitamin for Injection, Medium and Long Chain Fat Emulsion Injection, Nalmefene Hydrochloride lniecfion, Compound Amino Acid Injection（VII）, Multi-Trace Elements Injection (Ⅱ), Manidipine, Dolasetron Mesylate Injection,etc. Many of those products have been included in in National Essential Drugs List (NRDL) or Provincial Essential Drugs List, covered over 70% Grade A hospitals in China, established good professional brand awareness among clinical doctors and patients.
R&D Center has applied more than 40 patents and 4 patent licensed. At present, R&D Center has initialed and been developing more than 40 novel products, expecting over 10 getting on the market in 2 years. Many new products have important economic worth and medical values.